Plain-English translation of NCT06021483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study that collects real-world information about how Zepzelca performs in patients with metastatic small cell lung cancer. Researchers will track how well the medication works, what side effects patients experience, and whether there are any safety concerns that weren't caught in earlier testing. The study aims to understand how this treatment actually helps people in everyday medical practice, not just in controlled clinical trials.
This medication has already been approved for use, but doctors and the company want to learn more about how it performs when used by many different patients in real hospitals and clinics. There may also be gaps in what we know about safety and effectiveness that this study can help fill.
You likely qualify if…
You likely don't qualify if…
You would continue receiving your regular Zepzelca treatment as prescribed by your doctor. Researchers will collect information from your medical records about how you respond to the medication, any side effects you experience, and how your cancer progresses over time. You do not need to do anything special — the study simply tracks what happens during your normal medical care.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
South Korea
Enrollment target
~300 participants
Started
August 2023
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shinyoung Oh
Boryung Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.